First Japanese Conference on Combinatorial Chemistry and High Throughput Screening

1997 ◽  
Vol 2 (4) ◽  
pp. 181-181
Author(s):  
Richard A. Houghten
2002 ◽  
Vol 74 (19) ◽  
pp. 5105-5111 ◽  
Author(s):  
Radislav A. Potyrailo ◽  
Bret J. Chisholm ◽  
Daniel R. Olson ◽  
Michael J. Brennan ◽  
Chris A. Molaison

1997 ◽  
Vol 2 (3) ◽  
pp. 153-157 ◽  
Author(s):  
Geoffrey W. Mellor ◽  
Simon J. Fogarty ◽  
M. Shane O'Brien ◽  
Miles Congreve ◽  
Martyn N. Banks ◽  
...  

Identification of putative drug candidates by high throughput screening is assuming enormous importance within the pharmaceutical industry, driven by increasing numbers of valid therapeutic targets from both classical and molecular biological sources. Screening is an applied discipline that requires equipment and, more importantly, thinking that is fundamentally different from more traditional, lower throughput assay methodology. This article describes the process as applied to the discovery of selective antagonists of three chemokine receptor binding systems, from the original biological targets to chemically prosecutable lead compounds, which are currently being investigated using traditional medicinal and combinatorial chemistry methods.


2002 ◽  
Vol 23 (5) ◽  
pp. 20
Author(s):  
Harry Majewski

The biotechnology revolution offers great hope for new therapies based on rational approaches to target discovery and drug design based on genomics, proteomics, advanced chemistry (3-D modelling, combinatorial chemistry) and high throughput screening.


Author(s):  
Farhana Mosaddeque ◽  
Shusaku Mizukami ◽  
Awet A Teklemichael ◽  
Satoshi Mizuta ◽  
Yoshimasa Tanaka ◽  
...  

Author(s):  
S. Lakshmana Prabu

Modern chemistry foundations were made in between the 18th and 19th centuries and have been extended in 20th century. R&D towards synthetic chemistry was introduced during the 1960s. Development of new molecular drugs from the herbal plants to synthetic chemistry is the fundamental scientific improvement. About 10-14 years are needed to develop a new molecule with an average cost of more than $800 million. Pharmaceutical industries spend the highest percentage of revenues, but the achievement of desired molecular entities into the market is not increasing proportionately. As a result, an approximate of 0.01% of new molecular entities are approved by the FDA. The highest failure rate is due to inadequate efficacy exhibited in Phase II of the drug discovery and development stage. Innovative technologies such as combinatorial chemistry, DNA sequencing, high-throughput screening, bioinformatics, computational drug design, and computer modeling are now utilized in the drug discovery. These technologies can accelerate the success rates in introducing new molecular entities into the market.


Sign in / Sign up

Export Citation Format

Share Document